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doi:10.1016/j.jtcvs.2006.12.027bjectives: Our objectives were (1) to report operative and long-term mortality in
atients submitted to anterior surgical ventricular restoration, (2) to report changes
n clinical and cardiac status induced by surgical ventricular restoration, and (3) to
eport predictors of death in a large cohort of patients operated on at San Donato
ospital, Milan, Italy.
ethods: A total of 1161 consecutive patients (83% men, 62  10 years) had
nterior surgical ventricular restoration with or without coronary artery bypass
rafting and with or without mitral repair/replacement. A complete echocardio-
raphic study was performed in 488 of 1161 patients operated on between January
998 and October 2005 (study group). The indication for surgery was heart failure
n 60% of patients, angina, and/or a combination of the two.
esults: Thirty-day cardiac mortality was 4.7% (55/1161) in the overall group and
.9% (24/488) in the study group. Determinants of hospital mortality were mitral
alve regurgitation and need for a mitral valve repair/replacement. Mitral regurgi-
ation (2) associated with a New York Heart Association class greater than II
nd with diastolic dysfunction (early-to-late diastolic filling pressure 2) further
ncreases mortality risk. Global systolic function improved postoperatively: ejection
raction improved from 33%  9% to 40%  10% (P  .001); end-diastolic and
nd-systolic volumes decreased from 211  73 to 142  50 and 145  64 to 88 
0 mL, respectively (P  .001) early after surgery. New York Heart Association
unctional class improved from 2.7 0.9 to 1.6 0.7 (P .001) late after surgery.
ong-term survival in the overall population was 63% at 120 months.
onclusions: Surgical ventricular restoration for ischemic heart failure reduces
entricular volumes, improves cardiac function and functional status, carries an
cceptable operative mortality, and results in good long-term survival. Predictors of
perative mortality are mitral regurgitation of 2 or more, New York Heart
ssociation class greater than II, and diastolic dysfunction (early-to-late diastolic
lling pressure 2).
hronic ischemic heart failure (HF) is one of the major health care issues in
the Western world in terms of increasing number of patients affected, rate
of hospitalization, and costs.1,2 Despite optimal medical treatment, mortaliemains high in patients with ischemic HF and high functional class.3 The increase
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A
CDn ventricular volume after myocardial infarction is a com-
onent of the remodeling process; when left ventricular
LV) volume has increased to a certain extent and geometry
s markedly abnormal, HF progresses independently of neu-
ohormonal activation, according to the biomechanical
odel of HF expressed by Mann and Bristow.4 The concept
f a biomechanical model of HF clearly introduces the need
or therapies such as surgical ventricular restoration (SVR)
hat reduce LV volumes and restore geometry. SVR has
roven to be effective in improving pump function, clinical
tatus, and survival.5-8 The technique, first described b
atene9 and Dor and associates,10 applies not only to t
lassic aneurysm but also to ischemic dilated cardiomyop-
thy with akinesia or dyskinesia.6
SVR for patients with HF is increasingly performed, but
he results are somewhat difficult to compare because the
ype of damage (ie, true aneurysm or dilated cardiomyopa-
hy) is not well defined in the reported series.11 Moreover,
he reported studies are not randomized, and the question
hether adding SVR to coronary artery bypass grafting
CABG) will improve survival and clinical status can only
e answered by the ongoing STICH trial (Surgical T
ent of IsChemic Heart failure).12
In our center (San Donato Hospital, Milan, Italy), we
ave been performing SVR for ischemic cardiomyopathy
ince 1989, and a total of 1300 patients have been operated
n. The majority (1161 patients aged 63  10 years) had
nterior ventricular repair; the remaining either had poste-
ior repair (n  108) or an associated procedure other than
ABG or mitral repair (eg, ventricular septal defect closure,
ortic replacement, or Bentall operation; n  31). They are
ot included in the analysis because they deserve a separate
escription, and the aim of the present study is to describe
s homogeneous a population as possible (ie, after anterior
yocardial infarction).
The end points of this study are as follows: (1) operative
ardiac and all causes long-term mortality in the consecu-
Abbreviations and Acronyms
AUC  area under the curve
CABG  coronary artery bypass grafting
E/A  early-to-late diastolic filling pressure
EF  ejection fraction
HF  heart failure
LV  left ventricular
MR mitral regurgitation
NYHA New York Heart Association
ROC  receiver operating characteristic
STICH Surgical Treatment of IsChemic Heart
failure (trial)
SVR  surgical ventricular restorationive series of 1161 patients having anterior SVR (1989– o
34 The Journal of Thoracic and Cardiovascular Surgery ● Augu005); (2) changes in LV volumes, ejection fraction (EF),
nd New York Heart Association (NYHA) functional class
n 488 patients with a complete data set (1998-2005); and
3) predictors of operative mortality.
atients and Methods
atient Population
rom June 1989 to October 2005, a total of 1300 patients were
ubmitted to SVR at San Donato Hospital, Milan, Italy; 1161
atients had anterior SVR with or without CABG and with or
ithout mitral repair/replacement.
Demographic, clinical, echocardiographic, and procedural data
ere collected on an Excel database, which has been approved by
ur local ethics committee. The study group consists of 488
atients (1998-2005) with complete clinical and echocardiographic
ata available for the analysis (LV volumes, EF, NYHA class, and
egree of mitral regurgitation [MR]). Eighty-six were women and
02 men (63  10 years). Main indications for surgery were
ymptoms of HF, angina, and/or a combination of the two.
Diastolic function was graded as follows: 0  normal, 1 
bnormal relaxation, 2  pseudonormal, and 3  restrictive.
Echo assessment was made by transthoracic echocardiography
reoperatively and before discharge (7 to 10 days after the oper-
tion); a late echo study has been performed 6 months to 2 years
fter the operation in patients who return to the hospital for clinical
valuation (n  300).
Operative mortality was defined as 30-day mortality and late
ortality as mortality that occurred at follow-up (time from sur-
ery to death is available).
Follow-up was assessed by telephone interview with the pa-
ient, family, or family physicians; we contacted the regional death
egister if telephone interview failed.
urgical Technique
he technique has been described previously.7,13 In brief, th
rocedure is conducted on the arrested heart, with antegrade crys-
alloid or cold blood cardioplegia introduced in 2001. CABG is
rst performed, almost always on the left anterior descending
oronary artery to preserve the upper part of the septum and to
uarantee a complete revascularization. The mitral valve is re-
aired, when needed, through the ventricular opening with a dou-
le-armed stitch at the posterior annulus, from trigone to trigone,
nd the mitral orifice is undersized with a 24- to 26-mm Hegar
izer.14
Since July 2001 we have systematically introduced the use
f a mannequin (TRISVR; Chase Medical, Richardson, Tex)
lled at 50 to 60 mL/m2 to optimize size and shape of the new
entricle. The technique is a refinement of the Dor technique
nd allows standardizing the procedure. The mannequin is
seful when the ventricle is not very enlarged (to reduce the risk
f too small a residual cavity) or when the infarcted region is
ot clearly demarcated, as occurs in dilated cardiomyopathy
type III silhouette, as described by Strobeck and associate15).
n this circumstance, the transitional zone between scarred and
onscarred myocardium is not well defined and the mannequin
llows rebuilding the ventricle in an elliptical way and avoiding
phericalization, which, besides the reduction in size, is the
bjective of the procedure.
st 2007
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A
CDtatistical Analysis
o determine the association between independent risk factors and
ospital mortality, we applied the unpaired or paired Student t test,
nalysis of variance, or logistic regression analysis when appro-
riate. Predictability of the detected independent risk factors was
ested by a receiver operating characteristics (ROC) analysis, con-
idering an area under the curve (AUC) of at least 0.7 as predic-
ive, and sensitivity-specificity testing for determination of cutoff
alues. Long-term survival was analyzed by Kaplan–Meier sur-
ival curves, and differences between curves have been tested with
log–rank test. Statistics have been performed with a computer-
zed statistical package (SPSS 11.0; SPSS Inc, Chicago, Ill).
esults
reoperatively, 278 (57%) of the 488 patients were in
YHA functional class III/IV and 107 (22%) in class IV.
verall, diastolic dysfunction was abnormal in the great
ajority of patients (96%), with a pattern of abnormal
elaxation in 60% of patients, pseudonormal in 21%, and
estrictive in 15%.
The great majority had coronary disease suitable for
ABG; only 2.8% of the patients had nonsignificant coro-
ary lesions resulting from previous percutaneous translu-
inal coronary angioplasty. Seventy-two percent had mul-
ivessel disease, and CABG was performed in 95% (mean
umber of anastomoses 2.8 1.4); 92% received a thoracic
rtery graft on the left anterior descending coronary artery;
0% had patch reconstruction and 50% had a direct suture
o close the ventricle. A Q-wave anterior myocardial infarc-
ion was present in 66% of patients. MR, graded 1 to 4 at
cho study, was present in 78% of patients; it was mild in
he majority of patients and moderate to severe in 79 (18%)
f 441; in 47 patients the degree of MR was not assessed.
itral valve surgery (two mitral replacements) was per-
ormed in 18% (90/488); the indication to repair the valve
as grade 3/4 regurgitation or grade 2 regurgitation as-
ociated with annulus dilatation (40 mm).
arly Outcome
perative cardiac mortality was 4.7% (55/1161) in the
ABLE 1. Functional and cardiac status changes
Preop (n  488)
EDV (mL) 211 73 (200)
ESV (mL) 145 64 (131)
EF (%) 33 10 (33)
MR grade (not repaired) 1.1 0.8 (1)
MR grade (repaired) 3.0 1 (3)
PAP (mm Hg) 36 13 (34)
NYHA class 2.7 0.9
alues are mean  standard deviation (median). EDV, End-diastolic volume
ystolic pulmonary artery pressure; NYHA, New York Heart Association; n/averall consecutive series and 4.9% in the study group A
The Journal of Thoracic24/488). The main determinants of hospital mortality were
everity of MR and the need for mitral valve repair/replace-
ent. Severity of MR (graded 0–4) was significantly asso-
iated with hospital mortality at a logistic regression anal-
sis (P  .001), and its predictivity was confirmed by a
OC analysis (AUC of 0.81). Patients requiring mitral
alve repair/replacement had a significantly higher (13% vs
.0%; P  .001) operative mortality rate.
Cardiac function improved postoperatively and the de-
ree of MR significantly decreased (Table 1).
ate Outcome
linical follow-up was completed in 95% of the entire
opulation (average follow-up 56  48 months). Figure E
hows Kaplan–Meier long-term survival curve.
NYHA class improved from 2.7 0.9 to 1.6 0.7 (P
001). Repaired moderate-to-severe MR (2) decreased
ignificantly (P  .001) from 3.0  1 to 0.7  0.8 and to
.5  1.2 at follow-up (time from surgery 6 months to 2
ears; Table 1).
Figure 1 shows long-term survival stratified by preo
tive characteristics of the study group.
Recent experience (2001–2005). A subgroup of 254 pa-
ients (65  9 years) operated on in recent years was
rospectively collected and received a comprehensive echo
ssessment before and after the operation, including risk
actors, medical treatment, diastolic function parameters
early-to-late diastolic filling pressure [E/A] ratio, isovolu-
ic relaxation time, and deceleration time), rate of hospi-
alization, cardiac events, and procedures after surgery.
Cardiac operative mortality in this subgroup was 7.0%
18/254), not significantly different from that of the early
xperience. Preoperative factors being associated with hos-
ital mortality at univariate analysis are listed in Tabl
Owing to the relatively low number of events, we tested
or predictivity the various factors being associated with
ospital mortality at the univariate analysis using a ROC
nalysis and assuming as cutoff value for predictivity an
Early postop (n  452) Late postop (n  300)
142 50 (136)* 167  60 (153)*†
88 40 (81)* 104  50 (94)*†
40 10 (39)* 39  10 (39)*
0.7 0.6 (1)* 1.3  1.0 (1)
0.7 0.8 (1)* 1.5  1.2 (1.5)*†
31 10 (28) 34  13 (30)
n/a 1.6  0.7 (1)*
, end-systolic volume; EF, ejection fraction; MR, mitral regurgitation; PAP,
applicable. *P  .001 vs preoperatively. †P  .01 vs early postoperatively.; ESVUC less than 0.7.
and Cardiovascular Surgery ● Volume 134, Number 2 435
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4
A
CDThe results of this analysis are reported in Table E1.
ariables demonstrated an acceptable level of predictivity:
YHA class, EF, left atrial diameter, E/A ratio, and MR
everity. However, we could not determine an adequate
utoff value for EF, which is evidently associated with the
ospital mortality risk in a continuous fashion; the left atrial
iameter was strongly dependent on the MR severity; fi-
ally, the E/A ratio cutoff was settled at a value of 2.0, to
void the problem of distinguishing between impaired re-
axation profiles and pseudonormal patterns. As a result, we
aintained in our model three predictive factors for in-
ospital mortality: an NYHA class of III/IV, an E/A ratio
reater than 2.0, and an MR grade 2 or more. MR alone does
ot significantly increase operative mortality risk; con-
ersely, if associated with NYHA class III/IV, it determines
significant (P  .03) increase of the mortality risk; if a
ABLE 2. Factors associated with hospital mortality at the
Factor Survived
QRS duration (ms) 110 25
Hemoglobin value (mg/dL) 13.4 1.6
NYHA class 2.4 0.7
Ejection fraction 0.33 0.08
Left atrial diameter (mm) 43 8
Mitral flow E/A ratio 1.1 0.7
Diastolic pattern (graded 0–3) 1.4 0.7
Mitral regurgitation (graded 0–4) 1.3 1.2YHA, New York Heart Association; E/A, early-to-late diastolic filling pressure.
36 The Journal of Thoracic and Cardiovascular Surgery ● Augue vere diastolic dysfunction is also present, the risk is fur-
her (P  .001) increased (Figure 2).
Follow-up (20  10 months) was 100% complete in this
ubset of patients. Forty-four patients (18%) of 232 survi-
ors had cardiac hospitalization during the entire period
f follow-up. The most frequent causes of hospitalization
ere progressive HF (18/44), cardiac arrhythmias (8/44),
nstable angina (3/44), and stroke (1/44). Five (2.3%) of
15 patients (for whom procedures during hospitalization
ere available) had implantation of an internal cardioverter
evice, coupled with biventricular pacing in 2; 4 more
atients had biventricular pacing alone, for a total of 6
2.8%) patients with biventricular pacing; 3 patients re-
eived percutaneous transluminal coronary angioplasty.
verall, 82% of patients did not need hospitalization after
urgery.
Figure 1. Kaplan–Meier survival curve
in patients stratified by preoperative
characteristics. A, Diastolic diameter
(>70 mm. <70 mm). B, Preoperative
ejection fraction (>35%; <35%). C,
Preoperative New York Heart Associ-
ation (NYHA) classes I/II and III/IV. D,
Preoperative end-systolic volume (>80
mL; <80 mL).
variate analysis (subgroup of 254 patients)
Dead t P value
129 33 3.04 .003
12.4 1.9 2.71 .007
3.0 0.6 3.89 .001
0.27 0.1 3.13 .002
50  5 2.82 .005
2.1 1.4 4.25 .001
1.9 1.1 2.07 .04
2.5 1.3 4.11 .001unist 2007
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A
CDPatients with depressed LV function. A group of 301
62%) of the 488 patients had a preoperative EF of 35% or
ess; baseline clinical and hemodynamic characteristics are
eported in Table E2.
Cardiac operative mortality was 6.6% (20/301). Causes of
perative cardiac death were low cardiac output in 14, intrac-
able ventricular arrhythmias in 4, sudden death during reha-
ilitation in 1, and acute thrombosis of the graft in 1. T
hows cardiac function and clinical status before, early post-
peratively, and late postoperatively. Volume, EF, and NYHA
lass improved significantly after surgery; the degree of pre-
perative moderate-to-severe MR decreased significantly. We
ompared this group of patients with failing ventricles with the
87 patients with LV dilatation (end-diastolic volume index
00  36 mL/m2; end-systolic volume index  58  20
L/m2) and preoperative EF greater than 35% whose main
ndication for surgery was need for coronary revascularization.
e found that patients with better pump function benefit less
rom SVR: EF was 43% 6% preoperatively and changed to
5% 10% early postoperatively (P .02) and to 44% 8%
ate after surgery (P  .10). Operative cardiac mortality rate
as 2.1% (4/187) (2 test P  .02).
ABLE 3. Preoperative and postoperative (early and late af
reoperative EF < 35% (median)
Preop Early pos
iast Diam (mm) 66 9 (67) 61  9 (6
yst Diam (mm) 54 11 (55) 51  10 (
DV (ml) 235 73 (224) 154  52 (
SV (ml) 173 62 (161) 100  41 (
F (%) 27 6 (28) 36  9 (3
YHA class 2.8 0.8 (3) n/a
egree of MR (3) 3.6 0.5 (4) 0.8  0.9
F, Ejection fraction; Diast Diam, diastolic diameter; Syst Diam, systolic di
eart Association; MR, mitral regurgitation; n/a, not available; NS, not significa
The Journal of Thoracic 3
iscussion
he present article describes the largest single-center series of
atients with anterior SVR, and it is the largest that extends
ollow-up observation beyond 5 years.
Major findings from our results are as follow: (1) Sig-
ificant volume reduction and improvement in EF are ob-
erved at the predischarge echo evaluation, and this im-
rovement is still significant at late follow-up, despite a
light but significant increase in volumes and in MR, in
espect to early after surgery. The late increase in volume
ould be ascribed to loading conditions that are lower when
he patient is hospitalized, at rest. (2) Clinical status, as
valuated by NYHA functional class, is significantly im-
roved. (3) Eighty-two percent of patients are free from
ardiac rehospitalization. (4) Very few patients required an
nternal cardioverter device and biventricular pacing im-
lantation. (5) Long-term survival is promising also in pa-
ients with depressed cardiac function and high functional class.
he Biomechanical Model of HF
n a recent article Mann and Bristow4 described the concep
f a biomechanical model for HF to explain the progression
Figure 2. Risk stratification for operative mortal-
ity based on our predictive model (see text).
NYHA, New York Heart Association; E/A, early-
to-late diastolic filling pressure.
urgery) hemodynamic and functional data in patients with
Late postop P vs basal P vs postop
64  10 (65) .0001 .004
52  12 (52) .0003 NS
180  67 (169) .0001 .001
117  45 (112) .0001 .0002
36  9 (35) .0001 NS
1.6 0.6 (2) .0001 —
1.7  1.2 (1) .0001 .0001
r; EDV, end-diastolic volume; ESV, end-systolic volume; NYHA, New Yorkter s
top
2)
52)
146)
93)
6)
(1)
amete
nt.
and Cardiovascular Surgery ● Volume 134, Number 2 437
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4
A
CDf HF independently of the neurohormonal status of the
atient. According to these authors, our current neurohor-
onal models fail to completely explain disease progression
n HF. Current medical therapy acting against neurohor-
onal activation tends to slow progression but fails to arrest
he process of remodeling. In addition, many types of neu-
ohormonal inhibition proved to be ineffective or even
armful in patients with HF.16 To explain failure of neur-
ormonal antagonism, the authors focus on LV size and
eometry abnormalities as responsible for progression of
he disease. Geometric changes lead to structural abnormal-
ties of the myocytes and of the myocardium, which worsen
ardiac function and increase neurohormonal activation;
his may make the cardiovascular system less responsive to
ormal homeostatic control mechanisms.
Therapeutic strategies designed to interrupt the vicious
ycle will favorably affect the HF phenotype and the natural
istory of HF progression according to Mann and Brist4
VR is a surgical strategy that reduces LV volume, im-
roves geometry, and relieves ischemia.5-7,11,13
Our patients are left on HF medical therapy after surgery
94% are receiving diuretics, 81% angiotensin-converting
nzyme inhibitors, 34% beta-blockers, and almost all are
eceiving acetylsalicylic acid). In our common practice it is
requent to observe that some patients do clinically better
han could be expected from cardiac function status, and this
ismatch could be explained on the basis of the biome-
hanical model of HF in that SVR may not only revert the
emodeling process but also may make the cardiovascular
ystem more responsive to treatment and to neurohormonal
ctivation, once dimensions and geometry have improved.
neurysm Repair or HF Surgical Therapy?
VR as described by Dor and associates10 was developed a
more physiologic repair of LV aneurysm, compared
ith simple linear repair,9,17 but along with time and exp-
ience it was applied also to dilated ischemic cardiomyop-
thy, without the classic signs of the true aneurysm, that is,
severe distortion of the chamber with a discrete lesion,
ost often dyskinetic. In ischemic dilated cardiomyopathy,
he demarcation of the ischemic/necrotic lesion is no longer
resent and the curvature of the ventricle is flattened not
nly at the apical level but also at the basal portions15 I
ur early experience we mainly treated patients with true
neurysm, but more recently, ventricles that exhibit dilated
schemic cardiomyopathy are more frequently encountered.
schemic dilated cardiomyopathy is the result of more se-
ere damage of the entire chamber, including damage in the
emote zones, as the remodeling process progresses and is
ssociated with more severe hemodynamic abnormalities
higher pulmonary pressure, higher volumes, lower EF,
ore frequent MR). Moreover, in our more recent experi-nce, patients are significantly older and have more comor-
38 The Journal of Thoracic and Cardiovascular Surgery ● Auguidities, and we have increased the number of mitral repairs
it was 5% in the early experience and it is now 18%), which
ranslates into higher risk patients.
It has been known for many years that a true aneurysm
an be successfully treated with surgery, and the European
uidelines for diagnosis and treatment of HF give indication
or LV aneurysmectomy in patients with large, discrete LV
neurysm in whom HF develops.18 However, the new cha-
enge is to treat patients with dilated ischemic cardiomyop-
thy, and we think that SVR should be regarded as a viable
ption in modern interventional treatment of HF and not
nly as an aneurysm repair technique.
urgical Technique
VR is not a standardized technique. According to Dor and
olleagues,19 the use of a patch is mandatory, and m
ecently they introduced the use of a sizer; Caldeira and
cCarthy20 use a double purse-string suture techniqu
ickleborough and associates8 use a linear closure an
eptoplasty, sometimes with a patch, and it is difficult to say
hich other ways of rebuilding the LV are in the hands of
urgeons. We think that the technique should be standard-
zed to compare the results and to find the best way to treat
atients with HF. We have been using a sizer and shaper
ince 2001 in all our patients, and we think that the device
s helpful to standardize the procedure, reducing the risk of
estriction and of sphericalization of LV chamber.
itral Repair
unctional MR is frequently associated with postischemic
entricular dilatation, and its presence worsens prognosi21
t present, it has not been established whether, when, and
ow the mitral valve should be repaired during SVR. The
resence of moderate-to-severe MR and its surgical repair
arries a higher operative risk in our study group. It is
ifficult to distinguish whether the higher mortality is due to
he surgical procedure per sè, because patients with MR
ave worse clinical and hemodynamic conditions. In the
ost recent series, MR alone (2) did not increase the
n-hospital mortality risk; conversely, if associated with
YHA class III/IV and with severe diastolic dysfunction,
he risk is significantly increased. Our interpretation is that
R becomes a true predictor of hospital mortality only
hen the LV end-diastolic pressure, and therefore the left
trial pressure, are severely increased (as occurs whenever
he E/A ratio exceeds 2.0), leading to congestive HF and
evere functional impairment (NYHA class III/IV).
● On the basis of this experience, we consider the fol-
lowing to be the indications for SVR:
● Previous anterior myocardial infarction (either Q or
non-Q) as evaluated by electrocardiogram or cardiac
magnetic resonance.
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A
CD● LV dysfunction with dilatation of the ventricle and
regional asynergy (either akinetic or dyskinetic).
When LV asynergy is severe and diffuse, SVR can be
performed only if regions remote from the scar have
some degree of contraction detectable at rest or under
inotropic stimulus (like dobutamine test).
● HF symptoms are the first indication for SVR, but also
patients presenting with ventricular arrhythmias
and/or angina who need surgical revascularization
represent an indication for SVR (if the previous con-
ditions are present) to avoid further dilatation.
● For patients who are asymptomatic despite postinfarc-
tion LV dysfunction, we suggest that serial echocar-
diographic studies be performed to detect the first
signs of deterioration (ie, LV progressive enlargement
or decline in EF).
The following are contraindications:
● Severe right ventricular dysfunction (biventricular di-
lated cardiomyopathy) (absolute).
● Severe pulmonary hypertension not associated with
MR (relative).
● Severe regional asynergy without LV dilatation (ab-
solute).
● Restrictive diastolic pattern associated with high func-
tional class and MR (absolute).
When patients have relative or absolute contraindications
r when cardiac dysfunction is severe and diffuse, we per-
orm a stress echo dobutamine test. If contractility im-
roves, we perform SVR; if it does not improve and other
ptions such as transplantation are available, heart trans-
lant should be done. However, in some elderly patients
hen full medical therapy and other devices fail to improve
linical status, SVR can be the only treatment option and
oth patients and surgeons should be aware of an increased
ortality risk.
onclusions
ur study is observational and not randomized. Collection
f data is not uniform, being prospective in a minority of our
opulation, which remains the largest reported until now.
he severity of HF was based on NYHA functional class,
hich has limitations; we did not estimate quality of life,
hich is critical in this kind of patient with severe HF. We
xpect the STICH trial to answer all these critical questions.
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iscussion
r Andrew S. Wechsler (Philadelphia, Pa). This and Vincent
or’s series comprise the two largest observational series from
ingle centers on this operative procedure, at least to my knowl-
dge. Your results in this very challenging group of patients are
xcellent. I have four questions for you.
First, when I read the manuscript I noted that you used patch
losure only in about 50% of the patients. Should I take away the
mplication that many of these ventricles were not severely dilated,
r perhaps that you did the SVR as an incidental procedure when
he primary operation was in fact coronary revascularization?
My second question, and I have asked Dr Dor this same
uestion on several occasions, is this. When I did the calculations
ased on your own data, although there was an important increase
n EF, I found little or no increase in stroke volume. Are you
and Cardiovascular Surgery ● Volume 134, Number 2 439
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A
CDurprised that despite a reduction in end-diastolic volume, there is
o increase in stroke volume? Do you think this implies that the
rimary benefit of the procedure is, in fact, in reducing myocardial
xygen consumption at the same external work level, or is it
ossible that after the surgery there is, in fact, restricted filling of
he ventricles owing to a change in diastolic properties?
I noted that you indicated that pulmonary artery pressure
reater than 60 mm Hg was a warning sign to you and that you
ended not to operate on those patients, but I did not see within
our data any actual calculation of pulmonary artery pressure as a
ontinuous variable associated with enhanced mortality. Maybe
ou could comment on that.
Finally, in your analysis, MR and increased end-systolic vol-
me both turn out to be predictors of poor outcome and mortality.
id you analyze these as discrete variables, or is the MR just a
arker of a more severely dilated ventricle and not really different
rom ventricular size as a risk factor?
Dr Menicanti. Dr Wechsler, thank you very much for your
uestions, which are really crucial in this type of procedure. The
rst question concerns the type of closure that we have to employ.
he decision to use or not use the patch is determined by the anatomic
haracteristic of the ventricle. If the volume of the ventricle is not
oo big or the transitional zone is distal, the probability to close the
entricle without a patch is high. By contrast, if you have a very
ig ventricle or if you have calcification of the septum or if the
alls of the LV are thick, this condition normally implied the use
f a patch. I think that the patch is related to the real anatomic
ituation of the ventricle. That is an important tool in the decision-
aking to use a sizer. In effect, since we have started to use the
izer, the number of patches has increased.
Your second question is really more complicated. My idea, and
urely I can be wrong, is that there are two possibilities. First, in
ome patients we have seen, with magnetic resonance imaging,
ith echo, and with angiograms, that the basal portion presents an
ncreased contractility. Thus there is a hyperkinesia. When we
educe the volume, this portion goes to a normal contractility, and
onsequently the stroke volume does not change in this particular
ase. The other possibility is that there is a direct relationship
etween stroke volume and the preload. This relation is called the
ardiac functional relationship. The curve increases up to a certain
evel: at this point, increasing the preload does not increase the
troke volume, and this point represents the limit of the maximal
reload reserve. If we decrease the preload, decreasing the volume
f the LV cavity, the stroke volume does not change because we
re moving in the upper part of the curve. What has changed is the
reload reserve; the patient now has a preload reserve. This I think
s the reason why the patients do better, because finally they regain
reload reserve. In this situation we have improved mechanical
fficiency with reduced oxygen consumption for the same external
ork.
Pulmonary hypertension, as you rightly stated, is not consid-
red as a predictive factor in our analysis. This is determined by
he fact that we did not achieve statistical evidence, because for
his value in our database there are several missing data. Clinically,
e consider pulmonary hypertension a very important predictor of
omplication after the intervention, but unfortunately we were
nable to prove it statistically. We hope that by collecting data in d
40 The Journal of Thoracic and Cardiovascular Surgery ● Auguprospective way in the past 5 years we finally have the data to
emonstrate this aspect statistically.
According to MR and dimension, Marisa Di Donato in the
merican College of Cardiology meeting in 2003 demonstrated a
lear relationship between the degree of MR and ventricular end-
iastolic volume and shape. Particularly, there is a strict correla-
ion between the transverse diameter and MR. I think MR is the
ffect of a bigger ventricle, and particularly of a large ventricle that
resents an involvement of the inferolateral wall determined either
y an extension of an anterior infarction or by a second infarction
n this region. This is particularly true when we treat patients who
ave a double-sided myocardial infarction, an anterior and an
nferior. This type of patient, because the distance between the
apillary muscles is increased in a very important way, very
requently has MR. This group of patients is very difficult to treat
ecause the quality of the remote myocardium is poor.
Dr John V. Conte, Jr (Baltimore, Md). As one of the many
urgeons you have allowed to visit you in Milan and to watch you
perate, I want to thank you for sharing your wealth of experience.
know I have benefited from it greatly.
My question has to do with the role of ventricular restoration
nd transplantation in the treatment of end-stage heart disease.
here do you see transplantation in those patients who were in
lass III or class IV, the highest risk populations, who are poten-
ially candidates for each operation? Probably half of the patients
hat I operate on are candidates for either operation. When we
iscuss the risks and benefits and alternatives, it is hard sometimes
o provide a good black-and-white answer regarding what opera-
ion is appropriate. Can you give us any insight as to how you
ddress that?
Dr Menicanti. Thank you very much. You are perfectly right.
f we have a patient who has diastolic dysfunction, MR, NYHA
lass III or IV, and pulmonary hypertension, we know for sure that
ur mortality in this group of patients is high, 20% to 25%. It is
ery difficult to propose a surgical procedure like that to the
atient. There is no question that the heart transplant is the best
hoice. The problem is that the great majority of these patients are
t an age that is not suitable for heart transplant. The mean age of
ur group in the past 5 years is 65 years. Last year 300 transplants
ere performed in Italy—very few. If the patient is young, there is
o question that you have to send them to heart transplant. If the
atient is old with comorbidities, I think that this procedure is the
nly choice that we have.
Dr Robert A. E. Dion (Leiden, The Netherlands). We try to
ollow your example in Leiden, and last year we performed as
any as 50 SVRs according to Dor. I just have a short question
bout the sizing of the residual cavity in the LV. I hear that you
ecommend sometimes 50, sometimes 60 mL/m 2. I think it is a
ery important topic because it is probably a determining factor for
iastolic function. Could you elaborate on your thoughts about
hat? When are you using a smaller volume, when are you using a
igher volume, and why?
Dr Menicanti. That is a very nice question and not so easy to
nswer. From a very practical point of view, we use a small
olume (ie, 50 mL/m2) when the basal portion of the ventricle is
ormal, so that the transverse diameter is almost in the range of
ormality. When we have a more important dilatation or global
ilatation with dilatation also of the basal portion, with the idea to
st 2007
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ransverse diameter, we use a bigger size, 60 or 65 mL/m2 some-
imes. The choice of a bigger balloon is determined by dilatation
f the basal portion.
Dr David H. Adams (New York, NY). Dr Menicanti, can you
ell us a little bit more about this mitral valve subgroup in the sense
f what percent had primary anterior infarction, how you dealt
ith that, did you see an increased mortality with replacement
ersus repair, and did you use annuloplasty or repair all of these
rom inside the ventricle?
Dr Menicanti. All patients that we are describing in this group
ad an anterior myocardial infarction. Now, 20% of the patients
ho are operated on are also operated on for a mitral plasty. I think
he mortality in this group of patients is higher because the exten-
ion of the infarction is really very important and because the basal
ortion in this group of patients is not normal. Sometimes there is
nother infarction in that portion, sometimes there is fibrosis
ecause this situation lasts for such a long time and the myocytes
an be transformed into a fibroblast. The fact that we have in-
reased mortality depends, in my opinion, and I can be wrong, on
he fact that in this group of patients the residual contractile
yocardium is not so good as in the other situation. We have 13%
ortality when the mitral valve is approached. In the past 2 years
his mortality has decreased, probably because we are just a little
etter, but it is around 10%. I think that is determined by the
uality of tissue that we have. We approach the mitral valve in the
reat majority of the cases (95%) through the ventricle. When the
pening of the ventricle is small and it is difficult to see the valve,
e approach through the left atrium, but normally the ventricle that
resents MR is a big one.
Dr Robert H. Jones (Durham, NC). I congratulate Dr Meni-
anti, Dr Di Donato, and the others at San Donato on a beautiful
bservational study, remarkable for including all of your patients d
The Journal of Thoracicnd well describing their outcomes into subgroups. One subgroup
ou did not mention was the 22 patients that during the past 3 years
ou did choose to randomize into the STICH trial, and you are
dding also to the other hypothesis comparing the value of CABG
dded to medicine in this cohort. Would you share with us, first of
ll, the differences that made you at equipoise in those 22 patients
ompared with the others? How did you deal with telling the
amilies and the referring physicians that, on one hand, you are
oing the standard operation but in another situation you are
illing to randomize? You have taught many of us how to do this
peration. We in North America, as we are facing the opportunity
o put together a network to do more randomized clinical studies,
eed to learn from our European colleagues, who enroll more
atients into the STICH trial than we have in North America, how
o deal with this latter problem. Could you share your insight,
lease?
Dr Menicanti. Thank you, Dr Jones. This is really a problem
or us, because we believe in this procedure. The idea to randomize
he patients is sometimes very, very difficult. But what we did is a
ery simple issue. We know that this procedure is absolutely
antastic when there is a good or a relatively good basal portion,
nd we know the surgical mortality is really very low. So these are
he patients whom I did not randomize. Those whom I randomized
ere the patients with globally dilated cardiomyopathy, as we have
een in the echo in the beginning of my presentation, in whom I
now that the mortality is increased and in whom I have some
oubt about the outcome in terms of life expectancy. I randomize
atients if I am not sure they are not good candidates. And I
xplain that to them. Normally, they are in a very bad functional
lass, all are in full medical therapy, and they understand that their
ife expectancy is not long. They understand that we are trying to
o something to help, and they accept being randomized.
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ROC, Receiver operating characteristics; AUC, area under the curve; NYHA, Ne
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CDigure E1. Kaplan–Meier survival curve in the whole population.ABLE E1. ROC analysis for the factors being associated with hospital mortality at the univariate analysis
actor AUC Cutoff value Sensitivity Specificity
RS duration 0.65 — — —
emoglobin value 0.65 — — —
YHA class 0.71 3 70% 70%
jection fraction 0.72 — — —
eft atrial diameter 0.74 50 60% 80%
/A ratio 0.72 2.0 50% 90%
iastolic pattern 0.63 — — —
itral regurgitation 0.74 2 60% 80%w York Heart Association; E/A, early-to-late diastolic filling pressure.
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Menicanti et al Surgery for Acquired Cardiovascular DiseaseABLE E2. Baseline clinical and hemodynamic character-
stics in patients with preoperative EF < 35% (n  301)
Count (%)
ge 63  10
/F 244/57
YHA class
I 12 (4)
II 85 (28)
III 132 (44)
IV 69 (23)
itral regurgitation
None or trace 41 (16)
Mild (2) 160 (63)
Moderate (3) 22 (9)
Severe (4) 31 (12)
Not assessed 47
VEF (%)
N 301
Median 28
Mean  SD 27  6
VESV (mL)
N 229
Median 161
Mean  SD 173  62
VEDV (mL)
N 229
Median 224
Mean  SD 235  73
VEF, Left ventricular ejection fraction; LVESV, left ventricular end-systolic
olume; LVEDV, left ventricular end-diastolic volume; NYHA, New York
eart Association; SD, standard deviation.
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